10-K: BioCorRx Inc. Reports Full Year 2023 Results, Secures $11 Million Grant for Methamphetamine Use Disorder Treatment

BioCorRx Inc. announces its 2023 financial results, highlighting a net loss but also securing a significant $11 million grant for the development of a methamphetamine use disorder treatment.

Summary

• BioCorRx Inc. reported a net loss of $3.77 million for the year ended December 31, 2023, compared to a net loss of $4.38 million in 2022.
• The company's total revenue decreased by 58% to $89,160 in 2023 from $213,841 in 2022.
• Operating expenses decreased by $1.03 million, primarily due to reduced research and development, advertising, payroll, and consulting expenses.
• The company received a $11 million grant from the National Institute on Drug Abuse for the development of BICX104 for methamphetamine use disorder treatment.
• The company's cash balance at the end of 2023 was $65,222.
• The company has a working capital deficit of $6.24 million and an accumulated deficit of $78.1 million.
• The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While the company secured a significant grant and reduced operating expenses, the substantial revenue decline, net loss, and going concern warning from the auditor indicate significant financial challenges. The sentiment is therefore negative overall.

Positives

• The company secured a significant $11 million grant from the National Institute on Drug Abuse for the development of BICX104 for methamphetamine use disorder.
• The net loss decreased by $606,342 compared to the previous year.
• Operating expenses were reduced by $1.03 million, indicating cost-cutting measures.
• The company's research and development expenses decreased by $568,395.

Negatives

• The company experienced a significant decrease in revenue, dropping by 58% compared to the previous year.
• The company has a working capital deficit of $6.24 million and an accumulated deficit of $78.1 million.
• The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company's cash balance at the end of 2023 was $65,222.
• The company has a history of operating losses and anticipates future losses.

Risks

• The company has a history of operating losses and anticipates future losses.
• The company's ability to continue as a going concern is in doubt.
• The company needs to raise additional capital to fund its operations.
• The company's products have not yet generated significant revenues.
• The company faces competition in its industry.
• The company is subject to regulations of various local and federal government agencies.
• The company may not be able to protect or enforce its intellectual property rights.
• The company's share price could be volatile and its trading volume may fluctuate substantially.
• The company is subject to the Penny Stock rules of the SEC.
• The company faces risks related to Novel Coronavirus (COVID-19).

Future Outlook

The company anticipates continuing to incur operating losses as it executes its development plans for 2024 and other potential strategic and business development initiatives. The company will be dependent upon the raising of additional capital through placement of its common stock in order to implement the Companys business plan or by using outside financing.

Management Comments

• Management has developed a plan to continue operations, develop its products, and acquire technologies and assets.
• This plan includes continued control of expenses and obtaining equity or debt financing.

Industry Context

The company operates in the addiction treatment and pharmaceutical development industries, which are characterized by high regulatory hurdles, intense competition, and significant research and development costs. The company's focus on naltrexone-based treatments aligns with the growing need for non-addictive solutions to opioid and alcohol use disorders. The recent grant for methamphetamine use disorder treatment also positions the company to address a significant unmet need in the market.

Comparison to Industry Standards

• BioCorRx's financial performance is weak compared to established pharmaceutical companies, which typically have higher revenues and profitability.
• The company's reliance on grants and private financing is common among early-stage biotech companies, but it also indicates a higher level of risk.
• The company's focus on naltrexone implants is a niche area within the addiction treatment market, with limited direct comparables.
• The company's research and development spending is lower than that of larger pharmaceutical companies, which may impact its ability to bring new products to market quickly.
• The company's cash position is weak compared to industry standards, raising concerns about its ability to fund ongoing operations.

Management Changes

Legal Proceedings

• The company is involved in ongoing litigation related to a claim that Pellecome and Dr. Orbeck utilized the Companys confidential information to advance their own weight loss product.
• The company was ordered to pay Pellecome total costs and attorneys fees of $332,503, in addition to the $332,503 judgement the Company owes accrued interest of $57,412.

Related Party Transactions

• The company has entered into several subscription agreements and promissory notes with related parties, including Louis Lucido and Joseph Galligan.
• The company received advances from Louis C Lucido and Lourdes Felix.

Stakeholder Impact

• Shareholders face the risk of substantial dilution if the company raises additional capital.
• Employees may be affected by cost-cutting measures.
• Customers may be impacted by the company's financial instability.
• Creditors face the risk of non-payment due to the company's financial challenges.

Next Steps

• The company will continue to develop its products and acquire technologies and assets.
• The company will continue to control expenses and seek equity or debt financing.
• The company will continue research and development of BICX104 for methamphetamine use disorder treatment.

Key Dates

Keywords

BioCorRx, addiction treatment, naltrexone, opioid use disorder, alcoholism, methamphetamine use disorder, BICX104, FDA approval, grant, financial results, operating loss, revenue, clinical trial, pharmaceuticals, going concern